Medicina
Department
University of Kentucky
Lexington, Estados UnidosPublications in collaboration with researchers from University of Kentucky (20)
2023
-
Biolimus-eluting vs. other limus-eluting stents in NSTE-ACS: A pooled analysis of GLASSY and TWILIGHT
International Journal of Cardiology, Vol. 383, pp. 24-32
-
Bleeding and Ischemic Risks of Ticagrelor Monotherapy After Coronary Interventions
Journal of the American College of Cardiology, Vol. 82, Núm. 8, pp. 687-700
-
Clinically Driven Revascularization in High-Risk Patients Treated With Ticagrelor Monotherapy After PCI: Insights from the Randomized TWILIGHT Trial
American Journal of Cardiology, Vol. 208, pp. 16-24
-
Dyspnea-Related Ticagrelor Discontinuation After Percutaneous Coronary Intervention
JACC: Cardiovascular Interventions, Vol. 16, Núm. 20, pp. 2514-2524
2022
-
Bleeding and Ischemic Outcomes With Ticagrelor Monotherapy According to Body Mass Index
JACC: Cardiovascular Interventions, Vol. 15, Núm. 19, pp. 1948-1960
-
Safety and efficacy of ticagrelor monotherapy according to drug-eluting stent type: the TWILIGHT-STENT study
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, Vol. 17, Núm. 16, pp. 1330-1339
-
Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI: A Prespecified TWILIGHT Substudy
JACC: Cardiovascular Interventions, Vol. 15, Núm. 3, pp. 282-293
-
Ticagrelor with and without aspirin in patients with a prior coronary artery bypass graft undergoing percutaneous coronary intervention: the TWILIGHT-CABG study
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology, Vol. 18, Núm. 11, pp. e897-e909
2021
-
Impact of Age on the Safety and Efficacy of Ticagrelor Monotherapy in Patients Undergoing PCI
JACC: Cardiovascular Interventions, Vol. 14, Núm. 13, pp. 1434-1446
-
Sex Differences among Patients with High Risk Receiving Ticagrelor with or without Aspirin after Percutaneous Coronary Intervention: A Subgroup Analysis of the TWILIGHT Randomized Clinical Trial
JAMA Cardiology, Vol. 6, Núm. 9, pp. 1032-1041
-
Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR
European Heart Journal, Vol. 42, Núm. 45, pp. 4624-4634
-
Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD
European Heart Journal, Vol. 42, Núm. 45, pp. 4683-4693
2020
-
Ticagrelor alone vs.Ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS
European Heart Journal, Vol. 41, Núm. 37, pp. 3533-3545
2019
-
Ticagrelor with or without aspirin in high-risk patients after PCI
New England Journal of Medicine, Vol. 381, Núm. 21, pp. 2032-2042
2018
-
Telotristat ethyl in carcinoid syndrome: Safety and efficacy in the TELECAST phase 3 trial
Endocrine-Related Cancer, Vol. 25, Núm. 3, pp. 309-322
2013
-
Everolimus plus octreotide long-acting repeatable in patients with colorectal neuroendocrine tumors: A subgroup analysis of the phase III RADIANT-2 study
Oncologist, Vol. 18, Núm. 1, pp. 46-53
2008
-
Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: Insights from the STEEPLE trial
European Heart Journal, Vol. 29, Núm. 4, pp. 462-471
2007
2006
-
Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention
New England Journal of Medicine, Vol. 355, Núm. 10, pp. 1006-1017
-
Predictors of stroke within 30 days in patients with non-ST-segment elevation acute coronary syndromes
European Heart Journal, Vol. 27, Núm. 24, pp. 2956-2961